KraneShares MSCI All China Health Care Index ETF (KURE)
15.97
+0.00 (0.00%)
NYSE · Last Trade: May 22nd, 12:51 PM EDT
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
Via Benzinga · May 19, 2025
These ETFs beat the S&P 500 in April 2025’s turbulent market. Learn how TOLZ, VIXY, and KURE can help stabilize your investment strategy.
Via MarketBeat · April 15, 2025
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via Benzinga · April 11, 2025
China Stocks Look Set For A Rebound, Morgan Stanley Quant Strategists Saybenzinga.com
Investors in mainland China are rapidly unwinding their stock-index hedges, in an indication that a possible end to Chengdu’s lockdown and policies to stabilize the yuan will lead to a near-term market rally, reported
Via Benzinga · September 13, 2022

China's NPC meeting has sparked optimism in the market, with Chinese stocks and bonds rallying. Investors are hopeful for growth targets but remain skeptical.
Via Benzinga · March 7, 2025